| Endometrial Cancer |
1 |
1 |
| Cancer |
0 |
0.93 |
| Metastasis |
0 |
0.76 |
| Antineoplastic Drug |
0 |
0.64 |
| Targeted Cancer Therapy |
0 |
0.64 |
| Ovarian Cancer |
0 |
0.59 |
| Biologic Therapy |
0 |
0.57 |
| Toxicology |
0 |
0.45 |
| Surgery |
0 |
0.41 |
| Obesity |
0 |
0.3 |
| Chemotherapy |
0 |
0.21 |
| Distant Metastasis |
0 |
0.1 |
| Health Care Quality, Access, and Evaluation |
0 |
0.99 |
| Social Determinants of Health |
0 |
0.09 |
| Histology |
0 |
0.07 |
| Perioperative Care |
0 |
0.07 |
| Adjuvant Therapy |
0 |
0.03 |
| Hospital |
0 |
0.03 |
| Humanized Monoclonal Antibody |
0 |
0.03 |
| Lymph Node |
0 |
0.03 |
| Neoadjuvant Therapy |
0 |
0.03 |
| Ovary |
0 |
0.03 |
| Platinum |
0 |
0.03 |
| Prognosis |
0 |
0.03 |
| Resection |
0 |
0.03 |
| Residual Disease |
0 |
0.03 |
| Taxane |
0 |
0.03 |
| Tumor |
0 |
0.03 |